MX360666B - Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides. - Google Patents

Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.

Info

Publication number
MX360666B
MX360666B MX2013012971A MX2013012971A MX360666B MX 360666 B MX360666 B MX 360666B MX 2013012971 A MX2013012971 A MX 2013012971A MX 2013012971 A MX2013012971 A MX 2013012971A MX 360666 B MX360666 B MX 360666B
Authority
MX
Mexico
Prior art keywords
inflammatories
steroids
steroidal anti
povidone
compositions
Prior art date
Application number
MX2013012971A
Other languages
English (en)
Spanish (es)
Other versions
MX2013012971A (es
Inventor
Stein Jason
Weiser Michael
Capriotti Joseph
Liang Bo
Michael Samson C
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47139697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360666(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of MX2013012971A publication Critical patent/MX2013012971A/es
Publication of MX360666B publication Critical patent/MX360666B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2013012971A 2011-05-12 2012-05-11 Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides. MX360666B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485475P 2011-05-12 2011-05-12
PCT/US2012/037563 WO2012155062A1 (en) 2011-05-12 2012-05-11 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories

Publications (2)

Publication Number Publication Date
MX2013012971A MX2013012971A (es) 2013-12-12
MX360666B true MX360666B (es) 2018-11-13

Family

ID=47139697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012971A MX360666B (es) 2011-05-12 2012-05-11 Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.

Country Status (16)

Country Link
US (1) US20150038473A1 (cg-RX-API-DMAC7.html)
EP (1) EP2707006B1 (cg-RX-API-DMAC7.html)
JP (2) JP6072009B2 (cg-RX-API-DMAC7.html)
KR (1) KR101967938B1 (cg-RX-API-DMAC7.html)
CN (1) CN103957922A (cg-RX-API-DMAC7.html)
AR (1) AR086399A1 (cg-RX-API-DMAC7.html)
AU (3) AU2012253335B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013028735A2 (cg-RX-API-DMAC7.html)
CA (1) CA2835343A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013003016A1 (cg-RX-API-DMAC7.html)
CO (1) CO6821949A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013069A (cg-RX-API-DMAC7.html)
MX (1) MX360666B (cg-RX-API-DMAC7.html)
PE (1) PE20141070A1 (cg-RX-API-DMAC7.html)
TW (2) TWI632914B (cg-RX-API-DMAC7.html)
WO (1) WO2012155062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665195B2 (ja) 1995-05-19 1997-10-22 日本電気移動通信株式会社 Ｍｃａシステムにおける移動局の個別番号表示方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TW202126313A (zh) * 2011-09-16 2021-07-16 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
AU2013256130B2 (en) 2012-05-03 2017-12-21 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US20150366879A1 (en) * 2013-02-15 2015-12-24 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing antimicrobial metal
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US11052094B2 (en) * 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
EP3978003A1 (en) 2016-02-18 2022-04-06 Invirsa, Inc. Medical use of 5'-adenosine diphosphate ribose (adpr)
MA44676A (fr) 2016-04-14 2019-02-20 Azura Ophthalmics Ltd Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
BR112018072664A2 (pt) * 2016-05-05 2019-02-19 Veloce Biopharma, Llc composições e métodos para tratamento de inflamação e infecção do olho
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
CN116370408B (zh) * 2020-06-17 2025-12-02 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
CN112305115B (zh) * 2020-10-29 2022-08-23 诺峰药业(成都)有限公司 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法
KR20220062790A (ko) 2020-11-09 2022-05-17 정춘영 포비돈 아이오딘계 소독액
CA3203779A1 (en) * 2021-01-21 2022-07-28 Joon Youb Lee Ophthalmic composition
EP4282401A4 (en) * 2021-01-22 2025-01-29 Chengdu Ruimu Biopharmaceuticals Co., Ltd. Ophthalmic preparation administered by eye drops and used for preventing and treating dry macular degeneration and retinal light damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN105944105A (zh) * 2008-06-12 2016-09-21 前瞻生物治疗公司 一种眼科组合物中的防腐剂替代物聚维酮碘
AR079479A1 (es) * 2009-12-15 2012-01-25 Foresight Biotherapeutics Inc Composiciones oftalmicas no irritantes de povidona iodada
TW202126313A (zh) * 2011-09-16 2021-07-16 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物

Also Published As

Publication number Publication date
TW201311256A (zh) 2013-03-16
KR20140045375A (ko) 2014-04-16
EP2707006A1 (en) 2014-03-19
AR086399A1 (es) 2013-12-11
CA2835343A1 (en) 2012-11-15
AU2016222491A1 (en) 2016-09-22
KR101967938B1 (ko) 2019-04-10
EP2707006A4 (en) 2014-09-24
TWI717552B (zh) 2021-02-01
JP6072009B2 (ja) 2017-02-01
BR112013028735A2 (pt) 2017-12-05
CN103957922A (zh) 2014-07-30
EP2707006B1 (en) 2019-07-03
CO6821949A2 (es) 2013-12-31
AU2012253335B2 (en) 2016-08-04
MX2013012971A (es) 2013-12-12
JP6359619B2 (ja) 2018-07-18
ECSP13013069A (es) 2015-03-31
AU2018203492A1 (en) 2018-06-07
PE20141070A1 (es) 2014-09-14
US20150038473A1 (en) 2015-02-05
CL2013003016A1 (es) 2014-05-02
JP2017095474A (ja) 2017-06-01
TW201811340A (zh) 2018-04-01
JP2014516954A (ja) 2014-07-17
WO2012155062A1 (en) 2012-11-15
TWI632914B (zh) 2018-08-21
AU2012253335A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
MX360666B (es) Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
EP3021852A4 (en) Neuroactive steroids, compositions, and uses thereof
EP3035940A4 (en) Neuroactive steroids, compositions, and uses thereof
EP2970504A4 (en) Neuroactive steroids, compositions, and uses thereof
WO2013063315A3 (en) Methods and compositions for modification of the hprt locus
EP2747767B8 (en) Certain chemical entities, compositions, and methods
HK1217410A1 (zh) Erk抑制劑及其用途
DK2753632T3 (da) Neuroaktive steroider, sammensætninger og anvendelse heraf
EP3089780A4 (en) An incising implant for the prostatic urethra
EP3033424A4 (en) Compositions and methods for modulating rna
EP3027120A4 (en) Joining devices, kits and methods
MX2012013498A (es) Generador de aerosol.
WO2012166425A3 (en) Methods of amplifying whole genome of a single cell
EP3258939A4 (en) Neuroactive steroids, compositions, and uses thereof
MX2013012184A (es) Composiciones formadoras de gel in situ.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
EP3041512A4 (en) Fulvestrant compositions
EP2670763A1 (en) Certain chemical entities, compositions, and methods
EP3036005A4 (en) Compositions and methods for targeting connexin hemichannels
EE201100013A (et) Lhisolekute tekitamise meetod plokkjuhtimisega he- v?i mitmefaasilisele impedants-, kvaasiimpedants- ja transimpedants-tpi vaheldile
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
WO2014037519A3 (en) Compositions and methods
WO2012006355A3 (en) Dual stage active pixel devices and related methods
WO2014113492A3 (en) Anti-viral compounds

Legal Events

Date Code Title Description
FG Grant or registration